ABBV-CLS-7262

Novartis has partnered with BioAge Labs in a deal worth up to $550 million, gaining access to one of the world's largest human longevity datasets to develop treatments for age-related diseases.

Eli Lilly has entered a $415 million licensing agreement with UK-based Alchemab Therapeutics for ATLX-1282, a first-in-class antibody therapy for amyotrophic lateral sclerosis (ALS).

Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.

Calico's fosigotifator, targeting the integrated stress response, failed to meet primary or secondary endpoints in a Phase 3 trial for amyotrophic lateral sclerosis (ALS).

Denali Therapeutics' DNL343, an eIF2B agonist, did not meet the primary endpoint of slowing ALS disease progression in a Phase 2/3 trial.